You are here

Jazz Pharma

ASCO: Roche, Jazz's Zepzelca small cell lung cancer win leaves room for improvement

Fierce Pharma

Thu, 05/22/25 - 09:29 pm

small cell lung cancer

Jazz Pharma forks over $145M to shake off antitrust claims tied to narcolepsy drug Xyrem

Fierce Pharma

Thu, 04/10/25 - 11:42 am

Jazz Pharma to pay $145 million to settle narcolepsy drug antitrust case

MSN/Reuters

Tue, 04/8/25 - 10:53 pm

Chimerix engaged with 7 other biopharmas before choosing Jazz’s $935M deal—here’s why it won

Fierce Biotech

Sun, 03/23/25 - 11:45 pm

Jazz hands over $935M to buy Chimerix for near-approval cancer drug

Fierce Biotech

Wed, 03/5/25 - 12:03 pm

Jazz 'active and looking' at M&A deals of 'various sizes' as it wraps up Epidiolex patent fights: execs

Fierce Pharma

Wed, 02/26/25 - 11:27 am

Jazz to search for new chief as CEO plans retirement

BioPharma Dive

Mon, 12/16/24 - 11:15 pm

Jazz's HER2 bispecific snags FDA nod, teeing up showdown with AZ and Daiichi's Enhertu

Fierce Pharma

Thu, 11/21/24 - 11:18 am

Jazz's almost-withdrawn lung cancer drug Zepzelca extends life on top of Roche’s Tecentriq

Fierce Pharma

Tue, 10/15/24 - 11:03 am

extensive-stage small cell lung cancer

ESMO: Jazz HER2 bispecific posts 59% survival at 30 months in gastric cancer

Fierce Biotech

Mon, 09/16/24 - 09:50 am

gastroesophageal cancer

Jazz, Hikma must face 'reverse payment' claims over narcolepsy drug

Reuters

Tue, 08/27/24 - 10:32 pm

reverse payments

Jazz’s cannabidiol therapy flunks in Japanese Phase III trial

Clinical Trials Arena

Fri, 08/23/24 - 10:47 am

Jazz hits dud note as midphase essential tremor test misses endpoint

Fierce Biotech

Thu, 06/20/24 - 11:36 am

essential tremors

clinical trials

Alkermes and Jazz: Two Different Approaches to Neuroscience, Oncology Portfolios

BioSpace

Tue, 03/12/24 - 11:02 am

Jazz buys KRAS inhibitors from Redx in $880m deal

Pharmaphorum

Wed, 02/7/24 - 11:18 am

KRAS inhibitors

Jazz drops PTSD drug over phase 2 trial failure

Fierce Biotech

Fri, 12/22/23 - 09:39 am

FAAH inhibitors

clinical trials

How this CEO Built A Top 50 Pharma Company Focusing On Culture Day 1

Forbes

Wed, 12/6/23 - 12:00 am

Jazz halts sleep disorder med trial over 'visual disturbances' and CV effects

Fierce Biotech

Wed, 11/29/23 - 11:50 am

phase 1 sleep disorder

Sumitomo Pharma

Autifony swings $770.5m deal with Jazz for CNS drugs

Pharmaphorum

Tue, 11/14/23 - 09:22 am

neurological disorders

Jazz looks at strategic options, including possible sale or unit divestiture

Fierce Pharma

Fri, 10/20/23 - 11:58 am

Pages